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Purpose: Age-related macular degeneration (AMD) is a major cause of blindness in older adults and has a genetically
complex background. This study examines the potential association between single nucleotide polymorphisms (SNPs) in
the glucose transporter 1 (SLC2A1) gene and AMD. SLC2A1 regulates the bioavailability of glucose in the retinal pigment
epithelium (RPE), which might influence oxidative stress–mediated AMD pathology.
Methods: Twenty-two SNPs spanning the SLC2A1 gene were genotyped in 375 cases and 199 controls from an initial
discovery cohort (the Amsterdam-Rotterdam-Netherlands study). Replication testing was performed in The Rotterdam
Study (the Netherlands) and study populations from Würzburg (Germany), the Age Related Eye Disease Study (AREDS;
United States), Columbia University (United States), and Iowa University (United States). Subsequently, a meta-analysis
of SNP association was performed.
Results: In the discovery cohort, significant genotypic association between three SNPs (rs3754219, rs4660687, and
rs841853) and AMD was found. Replication in five large independent (Caucasian) cohorts (4,860 cases and 4,004 controls)
did not yield consistent association results. The genotype frequencies for these SNPs were significantly different for the
controls and/or cases among the six individual populations. Meta-analysis revealed significant heterogeneity of effect
between the studies.
Conclusions: No overall association between SLC2A1 SNPs and AMD was demonstrated. Since the genotype frequencies
for the three SLC2A1 SNPs were significantly different for the controls and/or cases between the six cohorts, this study
corroborates previous evidence that population dependent genetic risk heterogeneity in AMD exists.
Age-related macular degeneration (AMD) is the most
common  cause  of  severe  visual  impairment  in  Western
countries, rendering the disease a major public health issue
[1,2].
The prevalence of AMD increases strongly with age,
affecting 4% of the population over the age of 60 and more
than 10% of individuals older than 75 [2,3]. The early stages
of the disease are characterized by drusen, focal depositions
of extracellular material in Bruch’s membrane beneath the
retinal pigment epithelium (RPE) [4,5]. Late stages of the
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disease  include  two  forms:  an  atrophic  form  (geographic
atrophy  [GA])  and  an  exudative  form  (choroidal
neovascularization [CNV]).
AMD has a multifactorial etiology [6]. Age, smoking
history,  high  body  mass  index,  hypertension,  and
hypercholesterolemia influence AMD predisposition [7]. The
importance of genetic risk factors for AMD was highlighted
in several recent studies. In addition to the complement factor
H  (CFH)  gene,  genetic  association  studies  consistently
implicated at least four complement genes (factors B [CFB]
and I [CFI], components 2 [C2] and 3 [C3]) as well as one of
two genes (ARMS2 and HTRA1) in the chromosomal region
10q26.  Taken  together,  these  data  suggest  that  the
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657complement system, oxidative stress, mitochondrial function,
and extracellular matrix turnover play a role in AMD [8–14].
The RPE is one of the key tissues involved in AMD and
functions in several processes that are vital for preserving
sight. The RPE layer constitutes the outer blood-retinal barrier
and regulates transport ions, fluid, and metabolites between
the retina and the choroid [15]. Among other things, the RPE
transports glucose to the photoreceptors. Glucose supply to
the photoreceptors is essential since glucose is the preferred
energy substrate for the metabolically highly active retina
[16]. The sodium-independent glucose transporter SLC2A1 is
the  predominant  glucose  transporter  in  the  retina  [17,18].
SLC2A1 localizes to the apical and basolateral membranes of
the RPE [19]. According to Beatty and colleagues, the retina
is the ideal environment for generating free radicals and other
reactive oxygen species [20]. This may occur through similar
transport mechanisms through the inner and outer blood retina
barriers, and makes the retina an environment susceptible to
oxidative  damage.  Fernandes  et  al.  showed  in  2011  that
sustained  oxidative  stress  can  result  in  decreased  glucose
transport in retinal endothelial cells [21]. On the other hand,
increased  glucose  transport  and  SLC2A1  expression  are
upregulated  by  hypoxia  as  shown  by  Takagi  et  al.  [22].
Finally, increased serum glucose (hyperglycemia) might lead
to impaired antioxidant protection [23] and increased reactive
oxygen species (ROS) production [24]. In conclusion, DNA
sequence variations or altered expression levels in SLC2A1
may  influence  glucose  delivery  to  the  retina  and  thereby
profoundly affect local oxidative stress.
Variants in SLC2A1 have been associated with diabetic
retinopathy  [25],  type  2  (non-insulin-dependent)  diabetes
[26], diabetic nephropathy [27,28], and clear-cell renal cell
carcinoma [29]. Finally, expression of SLC2A1 in the retina
and brain is altered in different pathophysiological conditions,
including  hypoxia  [22,30],  Alzheimer  disease  [31],  and
epilepsy  [32].  We  hypothesized  that  genetic  variants  in
SLC2A1 could influence the glucose transport capabilities of
this transporter. This would lead to changes in the glucose
level in the RPE and neural retina, and alter the local oxidative
burden. Since multiple studies suggest that oxidative stress is
implicated in AMD [20,33–35], we performed an extensive
case-control  association  analysis,  to  test  whether  SLC2A1
gene variants are associated with this devastating disorder.
METHODS
Study populations: We employed five case-control studies
and one prospective cohort study, consisting of a total of 5,235
AMD cases and 4,203 ethnically- and age-matched control
subjects. The studies were approved by the Ethics Committees
of the Academic Medical Center Amsterdam, the Erasmus
Medical Center Rotterdam, the University of Würzburg, the
Age Related Eye Disease Study (AREDS) Access Committee,
and the Institutional Review Boards of Columbia University,
and the University of Iowa. All studies followed the tenets of
the  Declaration  of  Helsinki,  and  all  participants  provided
signed informed consent.
The initial discovery sample, the Amsterdam-Rotterdam-
Netherlands (AMRO-NL) study population, consisted of 375
unrelated individuals with AMD and 199 control individuals.
Subjects were all Caucasian and recruited from the Erasmus
University Medical Centre, Rotterdam, and the Netherlands
Institute for Neuroscience, Amsterdam, the Netherlands [36].
The second sample, the Rotterdam Study, is a prospective
cohort study aimed at investigating chronic diseases in older
adults, as previously described [37]. The eligible population
comprised all inhabitants aged 55 years or older of a middle-
class suburb in Rotterdam, the Netherlands.
The third sample, the Franconian AMD study (Würzburg,
Germany),  consisted  of  612  cases  and  794  age-matched
control subjects; the cases and controls originated from the
lower Franconian region of Bavaria, Germany [38].
The fourth sample, the AREDS (United States), included
two parts: 1) a randomized clinical trial to assess the effect of
supplemental  antioxidants  on  risk  of  AMD  and  cataract,
which began in April 1992 and ended in November 2001; and
2) a longitudinal study of progression of AMD. The study
participants were Caucasian, aged 55 to 80 years, and were
recruited at 11 centers in the United States from clinic and
general populations in those areas. The sample consisted of
936 individuals with AMD and 218 controls [39].
The  fifth  sample,  the  Columbia  University  (United
States)  study  population,  comprised  1,104  unrelated
individuals  with  AMD  and  368  unrelated  controls  of
European  American  descent,  recruited  at  Columbia
University [40].
The sixth sample, the Iowa University (United States)
study population, comprised 1,139 unrelated individuals with
AMD  and  403  unrelated  controls  of  European  American
descent, recruited at the University of Iowa [41].
Diagnosis  of  age-related  macular  degeneration:  Subjects
from  all  cohorts  underwent  ophthalmic  examination  and
fundus photography as described [36–41]. Signs of AMD
were graded according to the International Classification and
Grading system for AMD [42] except the AREDS [43] and
the Franconian AMD study [38] (Appendix 1).
Single nucleotide polymorphism selection: Twenty-two SNPs
were  selected  that  capture  common  variations  in  the
SLC2A1 gene. SNP data were from the Centre d’Étude du
Polymorphisme Humain (CEPH) population (Utah residents
with ancestry from northern and western Europe) by use of
the International HapMap Project. SNP selection was based
on  criteria  such  as  functional  relevance,  minor  allele
frequency  (MAF)>10%,  coverage  of  the  main  linkage
disequilibrium (LD) blocks, and tagging of the most common
haplotypes. Tag SNPs were selected with Tagger, an option
of  Haploview  [44]  (all  SNPs  were  captured  with  an  LD
tagging criterion of r2>0.8).
Molecular Vision 2012; 18:657-674 <http://www.molvis.org/molvis/v18/a72> © 2012 Molecular Vision
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leukocytes  after  venous  puncture  according  to  standard
protocols. A total of 1,536 SNPS, including 22 SLC2A1 SNPs,
were genotyped in the AMRO-NL study population using an
Illumina  GoldenGate  assay  on  a  BeadStation  500  GX
(Illumina Inc., San Diego, CA). This GoldenGate assay did
not  include  our  previous  published  complement  factor  5
(C5)  and  ERCC6  versus  AMD  screenings.  We  currently
screened all known rare and common genetic variants, which
met Illumina quality standards, in approximately 45 AMD
candidate genes (DB and AB; data not shown). The Rotterdam
Study was genotyped with the Illumina HumanHap 550K
array (Illumina Inc.). Quality control was performed using
PLINK  (version  1.01)  [37].  The  Franconian  AMD  study
sample was genotyped with TaqMan SNP Genotyping assay
for  the  SNPs  rs4660687:  A>C  and  rs3754219:  A>C.
Rs841853 was genotyped with PCR (forward primer: 5′-CCT
CAG  GGA  ATA  AAG  CTA  GTC  TCC  AG-3′;  reverse
primer:  5′-AGA  CCA  GCC  AGA  GGT  TCC  AAA-3′)
followed by XbaI digestion and restriction fragment length
analysis. The AREDS, Columbia, and Iowa samples were also
genotyped with Taqman SNP genotyping assays. All TaqMan
assays were performed on ABI7300 Real-Time PCR systems
(Applied Biosystems, Foster City, CA).
Statistical analysis: To account for multiple comparisons, we
determined, initially, three different significance tresholds for
the Golden-Gate Assay in the AMRO-NL study. The first was
an overall Bonferroni corrected significance threshold per
SNP (0.05/ total nr of SNPs on the Illumina GoldenGate assay
[n=1536; p=3.25 × 10−5]). However, this significance level
takes neither the large difference in the MAF of the SNPs
screened nor the co-occurrence of SNP variation in LD blocks
into account. Thus, next to this overall significance level, we
also applied a gene-wise significance threshold by dividing
the nominal alpha by the number of SNPs per gene. The gene-
wise significance threshold for SLC2A1 is 0.05/ total nr of
SLC2A1  SNPs  on  the  Illumina  GoldenGate  assay  (n=22;
p=2.27 × 10−3). Finally, as a positive control to determine the
true  statistical  significance  levels  of  our  assay,  we  also
included  complement  factor  3  (C3)  polymorphisms,  well
known in the literature to associate with AMD. We found an
association with multiple C3 SNPs and AMD in our study,
with p values ranging from p=0.02 to p=0.0003 (not shown).
The p values of our initial SLC2A1 association findings ranged
from p=0.02 to p=0.0006 (see the Results section).
In  all  studies,  we  employed  the  χ2  test  to  test  SNP
distributions  for  conformity  with  the  Hardy–Weinberg
equilibrium (HWE). We compared allele frequencies between
cases  and  controls  using  Fisher’s  exact  test  statistic.  We
estimated odds ratios (ORs) and 95% confidence intervals
(CIs) for the risk of AMD with logistic regression analysis and
represent the risk of disease (AMD versus no AMD) in the
genetic risk group divided by the risk of disease in the non-
risk group (non-carriers). For the AMRO-NL study and the
Rotterdam Study, we adjusted all ORs for age and gender. To
determine  whether  SLC2A1  SNPs  were  independent  risk
factors,  we  estimated  their  effects  in  a  model  with  an
additional adjustment for known (genetic) risk factors: CFH
Y402H,  LOC387715  A69S,  and  smoking  and  their
interactions  with  the  SLC2A1  SNPs.  All  analyses  were
performed in Statistical Package for Social Sciences (SPSS)
for  Windows  software  (release  16.0;  IBM-SPSS,  Inc.,
Chicago,  IL).  In  the  Rotterdam  Study,  we  performed
association  tests  using  logistic  regression  in  the  PLINK
software package (version 1.01) [45]. We performed a meta-
analysis  using  Review  Manager  (RevMan)  Version  5.0.
assuming an additive genetic model. We tested heterogeneity
between studies using Cochran’s Q statistic [46]. In addition,
we quantified heterogeneity with the I2 metric [46]. In the
absence of heterogeneity (I2 statistic <25%), we used the fixed
effects model (the Mantel-Haenszel method) to calculate the
pooled OR; otherwise, we used the random effects model (the
DerSimonian  and  Laird  method).  We  compared  genotype
frequencies between the study populations with the Pearson
χ2 test.
RESULTS
The AMRO-NL sample: associations of SLC2A1 SNPs with
age-related macular degeneration: We initially genotyped 22
SNPs in 375 unrelated AMD patients and 199 controls of the
AMRO-NL study population. Demographic characteristics of
the AMRO-NL study population and all study populations
used  were  essentially  described  previously  [36,47].  SNP
genotype frequencies were tested in controls and conformed
to the HWE, except for two SNPs (rs12407920, rs16830101;
p=0.04) that were removed from further analysis. HWE data,
genotype  distributions,  and  allelic  p  values  for  the  22
SLC2A1 SNPs are presented in Table 1. Three out of the 22
SNPs showed a significant allelic association with AMD:
rs3754219  (p=0.0011),  rs4660687  (p=0.0157),  and
rs841853 (p=0.0006). The reported initial associations in the
AMRO-NL  study  did  not  reach  the  overall  Bonferroni
significance  threshold,  but  two  out  of  three  SNPs
(rs3754219 and rs841853) passed the gene-wise threshold as
well as the positive control (C3) association threshold. The
risks of AMD for these three SLC2A1 SNPs, adjusted for age
and gender, are presented in Table 2. When all AMD cases
and controls of the AMRO-NL study were included in the
analysis, we observed significant association with all three
SNPs. SNP (rs3754219) showed a protective effect for AMD
(OR 0.44; 95% CI 0.26–0.74). The other SNPs showed a risk
increasing effect (rs4660687, rs841853) with the highest ORs
seen for homozygous carriers of the risk alleles of rs841853
(OR 2.24; 95% CI 1.13–4.41). We subsequently analyzed the
early and late AMD subgroups separately. For early AMD,
we  observed  a  significant  association  only  for  rs4660687
(Table 2). For the late AMD subgroup, we observed a similar
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661effect as seen for all AMD cases: a significantly increased risk
for hetero- and homozygote carriers of rs841853 and for the
heterozygote carriers of rs4660687 and a protective effect for
homozygote carriers of rs3754219 (Table 2). Adjusting for
Figure 1. Linkage disequilibrium (LD) display in Haploview of (A) the three SLC2A1 single nucleotide polymorphisms (SNPs) rs3754219,
rs4660687, and rs841853. Left: D’(D prime), Right: r2 (r square) (B) all the 22 SNPs in the SLC2A1 gene with minor allele frequency>10%
screened in this study and illustrating the nine distinct haplotype blocks. LD scores: D' (D prime) displays the raw D' value, which is the
normalized covariance for a given marker pair and the correlation coefficient r2 (r square). Darker shades represent stronger LD.
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662three  prominent  AMD  risk  factors  (CFH  Y402H,
LOC387715 A69S, and smoking) did not modify the relation
of any of the SLC2A1 SNPs with AMD (data not shown).
Independent replication studies have variable outcomes: The
three  SNPs  that  showed  allelic  and  genotypic  association
(rs3754219,  rs4660687  and  rs841853)  were  selected  for
replication in five study populations of comparable ethnic
(Caucasian)  composition:  the  Rotterdam  Study,  the
Franconian AMD study, the AREDS, Columbia University,
and the University of Iowa. Figure 1A shows the LD map in
Haploview  of  the  three  SNPs  and  the  corresponding  LD
scores, and Figure 1B shows the LD map of all 22 SLC2A1
SNPs with minor allele frequency>10% screened in this study
and illustrates the nine distinct haplotype blocks. The three
associated SNPs are in two different blocks in the SLC2A1
gene (rs3754219 and rs841853 are in the same LD block). As
can be seen, two SNPs (rs1770811 and rs841856) without
allelic association are inside the LD block with rs3754219 and
rs841853.  Obviously,  the  observed  (non-)  associations
depend on the informativeness (MAF) of the specific SNPs
and the distribution of alleles. A possible explanation might
also be differences in LD patterns (between the SNPs in the
same wild-type LD block) with an untyped causal variant.
Replication  studies  for  SLC2A1  single  nucleotide
polymorphism  rs3754219:  The  results  of  replicating  the
association between SNP rs3754219 and AMD (all cases or
late AMD and controls only) are presented in Appendix 2.
Genotype frequencies for rs3754219 followed the HWE in all
study populations (data not shown). When we included all
AMD  cases,  we  observed  no  significant  association  with
rs3754219  in  any  of  the  replication  cohorts.  When  we
analyzed the AMD subgroups separately (Appendix 3), we
found a borderline significant effect in the Rotterdam Study
for the CNV cases (p=0.0554). In line with the results of the
discovery cohort, we observed this possible protective effect
for homozygous carriers of the risk allele. In contrast, we
observed  a  risk  increasing  association  effect  between
SLC2A1  rs3754219  and  AMD  (subtype)  in  the  Columbia
University study: This effect occurred in the homozygous
carriers of the risk allele (OR 1.66; 95% CI 1.01–2.72) in the
GA group (Appendix 3). No significant associations were
seen in the other replication cohorts.
Replication  studies  for  SLC2A1  single  nucleotide
polymorphism  rs4660687:  The  results  of  replicating  the
association between SNP rs4660687 and AMD (all cases or
late AMD and controls only) are presented in Appendix 2.
Genotype  frequencies  followed  the  HWE  in  all  study
populations (data not shown). The association of rs4660687
with AMD, as found in the AMRO-NL study, was confirmed
in the Rotterdam Study (OR 1.39; 95% CI 1.12–1.72). Thus,
both Dutch populations showed a significant association for
all AMD cases. However, in the other replication cohorts, no
significant  association  was  found.  Upon  subtype  analysis
(Appendix 4), we found a significant association between
rs4660687 and the early AMD cases of the Rotterdam Study.
Again, this effect was present in both Dutch populations. For
this SNP, we also found a possible opposite effect: in the
Franconian AMD study, we observed a significant protective
effect in the mixed AMD subgroup instead of a risk increasing
effect. This was seen for hetero- and homozygous carriers of
the risk allele. In the three cohorts from the United States, we
found no significant associations for AMD.
Replication  studies  for  SLC2A1  single  nucleotide
polymorphism  rs841853:  The  results  of  replicating  the
association between rs841853 SNP and AMD (all cases or late
AMD  and  controls  only)  are  presented  in  Appendix  2.
Genotype  frequencies  followed  the  HWE  in  all  study
populations (data not shown). The association of rs841853
with AMD, as found in the AMRO-NL study, was confirmed
in the AREDS sample: We observed a significant effect for
homozygous carriers of the risk allele (OR 2.07; 95% CI 1.14–
3.76) in all AMD cases. In the other replication cohorts, no
significant  association  was  found.  Upon  subtype  analysis
(Appendix 5), we observed a significant association between
rs841853  and  the  CNV  cases  of  the  Rotterdam  Study.
Additionally,  in  the  AREDS  sample,  we  observed  a
significant association between rs841853 and late AMD cases
(Appendix 2). The effect was particularly profound for the
CNV and GA subpopulations (Appendix 5). Finally, in the
Columbia cohort, we found a significant association between
rs841853 and the GA cases, but this effect was in the opposite
direction:  heterozygotes  showed  a  protective  association
instead of a risk increasing effect for GA. We also saw this
protective effect for the late AMD cases of the Columbia
cohort  (Appendix  2).  We  saw  no  significant  associations
between rs841853 and AMD subtypes in the two other study
populations.
Meta-analysis: heterogeneity of effect: We performed a meta-
analysis  of  the  putative  association  between  AMD  and
SLC2A1 SNPs rs3754219, rs4660687, and rs841853 across
the independent study populations.
We  quantified  the  effect  and  assessed  the  potential
heterogeneity of effect between studies (with Cochran’s Q test
and the I2 metric, Table 3 and Figure 2, Figure 3, and Figure
4). For rs3754219, significant heterogeneity of effect between
studies  was  demonstrated,  not  only  for  all  AMD  cases
combined  (p=0.006;  I2=70%)  but  also  for  CNV  (p=0.02;
I2=65%)  and  late  AMD  cases  (p=0.002;  I2=73%).
Furthermore, moderate (not significant) heterogeneity was
seen for the GA and CNV + mixed cases, respectively. No
heterogeneity was found for the early and mixed AMD cases
(Table 3). For the groups with I2 values >25%, we used the
random effects model (the DerSimonian and Laird method)
to  calculate  the  pooled  OR;  otherwise,  in  absence  of
heterogeneity (I2 statistic <25%), we used the fixed effects
model  (the  Mantel-Haenszel  method).  The  summary  OR
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664indicated that no significant association between rs3754219
and  (all  clinical  subtypes  of)  AMD  was  found  over  all
populations  (Figure  2).  Similarly,  meta-analysis  for
rs4660687  showed  significant  heterogeneity  (p=0.02;
I2=64%) for all AMD cases. Moderate (but not significant)
heterogeneity  was  seen  for  the  AMD  subtypes  with  the
exception of the GA, CNV, and CNV+ mixed cases where no
or low heterogeneity was detected (Table 3). Using a random
or  fixed  effects  model  (depending  on  the  amount  of
heterogeneity), we found no association between rs4660687
and  (all  clinical  subtypes  of)  AMD  over  all  populations
(Figure  3).  Also  for  rs841853,  the  between-study
heterogeneity was significant; not only for all AMD cases
combined (p=0.008; I2=68%) but also for CNV (p=0.0005;
I2=80%)  and  late  AMD  cases  compared  to  the  controls
(p=0.002;  I2=74%).  We  saw  moderate  (not  significant)
heterogeneity  for  CNV+  mixed  cases  and  saw  no  or  low
heterogeneity for the early, GA, and mixed cases (Table 3).
Using a random or fixed effects model (depending on the
amount of heterogeneity), the summary OR indicated that no
significant associations were present between rs841853 and
(all clinical subtypes of) AMD (Figure 4).
Genetic heterogeneity between study populations: To explore
the genetic contribution to the heterogeneity of effect between
the populations, we assessed the differences in MAF and
genotype frequencies between the study populations (Table 2
and Appendix 2). For rs3754219, we observed MAFs in the
control populations ranging from 41% (Columbia University)
to 52% (AMRO-NL). For the cases, we observed rs3754219
MAFs varying from 41% (AMRO-NL) to 46% (Franconian
AMD  study).  For  rs4660687,  we  observed  MAFs  in  the
control populations ranging from 34% (AMRO-NL) to 43%
(AREDS). For the cases, the rs4660687 MAFs were nearly
similar  (41%–43%)  with  the  exception  of  the  Franconian
AMD study (MAF=37%). For rs841853, the MAF ranged
from 25% (AMRO-NL) to 33% (the Franconian AMD study)
in the control groups. For the cases, we observed rs841853
MAFs  varying  from  30%  (Iowa)  to  35%  (AMRO-NL).
Subsequently, we compared the genotype frequencies of the
controls between study populations for all three SNPs using
Figure 2. Meta-analysis of rs3754219 for its association with all AMD cases (A), early (B), GA (C), CNV (D), mixed (E), CNV + mixed
(F), and late AMD (G) cases in six independent study populations. AMD=age-related macular degeneration; GA=geographic atrophy;
CNV=choroidal neovascularization; Mixed cases (combination of GA + CNV). Odds ratios (ORs, squares) and 95% confidence intervals (CI;
horizontal lines) are presented for each study. Also shown is the black diamond of the summary OR using either the additive Mantel-Haenszel
fixed effects model when heterogeneity was absent (I2 <25%) or the additive DerSimonian and Laird random effects model when heterogeneity
was present (I2 >25%). Heterogeneity between studies was tested using Cochran's Q statistic and the I-square statistic for inconsistency.
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665the Pearson χ2 test: for rs3754219 and rs841853, we found
significant differences with χ2 overall p values of 0.027 and
0.024,  respectively  (Table  4).  We  found  no  significant
differences  in  genotype  frequencies  between  the  control
groups  for  rs4660687.  Next,  we  compared  the  genotype
frequencies  for  all  populations’  cases:  the  rs3754219
genotype frequencies of all AMD cases combined or AMD
clinical subtypes of the six study populations did not show
significant differences. For rs4660687, we found a significant
(χ2  overall  p  value=0.002)  difference  in  the  genotype
frequencies of all AMD cases and the CNV+ mixed cases
(χ2 overall p value=0.049). For rs841853, we found significant
differences in the genotype frequencies for the CNV subtype
(p value=0.024; Table 4). Detailed results of the individual
analysis are presented in Appendix 6.
DISCUSSION
Three out of 22 SLC2A1 SNPs tested showed a significant
allelic and genotypic association with AMD in the AMRO-
NL  discovery  cohort.  Replication  of  these  three  SNPs
(rs3754219, rs4660687, and rs841853) in five independent
cohorts  yielded  inconsistent  association  results.  Meta-
analysis revealed no overall association between SLC2A1 and
AMD.  For  all  three  SNPs,  we  observed  significant
heterogeneity  of  effect  and  high  inconsistency  across  the
study populations. Using a random or fixed effect model, we
calculated pooled ORs, which were not significant for any of
the SNPs in any of the studies. Such findings are not unique:
one  of  the  greatest  challenges  in  interpreting  genetic
association studies is the lack of consistent reproducibility
[48]. Hirschhorn and colleagues (2002) reviewed more than
600 positive associations between common gene variants and
disease and found that the majority is not robust. Of the 166
presumed  associations,  which  were  studied  three  or  more
times, only six were consistently replicated [49]. Similarly, a
meta-analysis of 301 published studies covering 25 different
reported  associations  showed  that  less  than  half  of  the
associations  were  consistent  across  the  different  study
populations  [50].  For  AMD,  at  least  two  recent  studies
highlight  the  lack  of  consistent  replication  of  association
across  large  population  studies:  initial  associations  found
between AMD and SNPs in the Toll-like receptor 3 [51] and
Figure 3. Meta-analysis of rs4660687 for its association with all AMD cases (A), early (B), GA (C), CNV (D), mixed (E), CNV + mixed
(F), and late AMD (G) cases in six independent study populations. AMD=age-related macular degeneration; GA=geographic atrophy;
CNV=choroidal neovascularization; Mixed cases (combination of GA + CNV). Odds ratios (ORs, squares) and 95% confidence intervals (CI;
horizontal lines) are presented for each study. Also shown is the black diamond of the summary OR using either the additive Mantel-Haenszel
fixed effects model when heterogeneity was absent (I2 <25%) or the additive DerSimonian and Laird random effects model when heterogeneity
was present (I2 >25%). Heterogeneity between studies was tested using Cochran's Q statistic and the I-square statistic for inconsistency.
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666the  Serpin  Peptidase  Inhibitor,  Clade  G,  member  1
(SERPING1) genes [52] could not be replicated independently
[47,53].  For  SLC2A1  SNP  rs841853  and  diabetic
nephropathy, a similar inconsistent association result across
large study populations was reported [54].
The  SLC2A1  SNPs  rs841853,  rs3754219,  and
rs4660687 do not reside within known regulatory region(s) of
the  SLC2A1  gene  (i.e.,  promoter,  enhancers,  and  silencer
elements).  We  entered  these  SNPs  into  the  SNPExpress
database to find out that these SNPs apparently indeed do not
affect gene expression. Obviously, the possibility exists that
one or more of the SNPs tag a true causal variant in or adjacent
to  the  SLC2A1  gene  that  determines  the  possible  genetic
susceptibility  to  AMD.  Interestingly,  Tao  and  coworkers
(1995)  examined  whether  the  association  between  the
rs841853 SNP and non-insulin-dependent diabetes mellitus
could be due to other causal variants in LD with rs841853.
Initially, such a variant was not found [55]. However, after
seven years, Ng et al. (2002) found a new putative causal
variant in LD with rs841853 in an insulin-responsive enhancer
element, potentially regulating SLC2A1 gene expression and/
or function [56].
One  of  our  study  limitations  is  that  we  selected  for
common SLC2A1 SNPs, with MAFs>10%. Consequently, we
could have missed variants with MAFs<10% and outside the
coding region that might influence the disease phenotype. In
addition, because our initial association values found in the
AMRO-NL study passed only two out of three significance
levels used (see Material and Methods), there was, initially, a
somewhat  increased  possibility  of  false-positive
association(s). Furthermore, as we and others have discussed
extensively  elsewhere  [36,57],  inconsistent  replication  in
genetic-association  studies  can  be  caused  by  numerous
factors,  including  chance,  variation  in  study  design,
phenotypic AMD (grading) differences, and genotype errors
[58]. Indeed, the effect of these factors is stronger in small
cohorts, such as defined by clinical subtypes of AMD. These
factors may have played a role in our study [36]. In addition,
genetic heterogeneity between populations may significantly
affect the outcome of association studies [57]. It may be not
Figure 4. Meta-analysis of rs841853 for its association with all AMD cases (A), early (B), GA (C), CNV (D), mixed (E), CNV + mixed (F),
and  late  AMD  (G)  cases  in  six  independent  study  populations.  AMD=age-related  macular  degeneration;  GA=geographic  atrophy;
CNV=choroidal neovascularization; Mixed cases (combination of GA + CNV). Odds ratios (ORs, squares) and 95% confidence intervals (CI;
horizontal lines) are presented for each study. Also shown is the black diamond of the summary OR using either the additive Mantel-Haenszel
fixed effects model when heterogeneity was absent (I2 <25%) or the additive DerSimonian and Laird random effects model when heterogeneity
was present (I2 >25%). Heterogeneity between studies was tested using Cochran's Q statistic and the I-square statistic for inconsistency.
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668coincidental that we found positive replication for SLC2A1
SNP rs4660687 in the early cases of the Dutch populations
(the AMRO-NL and the Rotterdam Study cohorts), where the
allele and genotype distributions are more or less similar, but
not in other populations.
Interestingly, we found opposite associations for the three
SLC2A1 SNPs (rs3754219, rs4660687, and rs841853) in two
highly  comparable  populations.  A  similar  “flip-flop”
association was previously found by Lin et al. in two different
ethnic populations [59]. The source of this opposite effect in
our studies is not clear, and remains to be elucidated.
To assess the contribution of “the genetic factor” in detail,
we  compared  the  genotype  frequencies  of  all  study
populations in relation to the heterogeneity of effect. The
Pearson  χ2  test  showed  that  genotype  frequencies  for
SLC2A1 rs3754219 and rs841853 were significantly different
for  the  controls  of  the  six  individual  populations.  For
rs4660687, we observed significant differences in genotype
distributions  for  the  cases.  For  several  SLC2A1  SNPs,
including  rs841853,  genuine  genetic  differences  between
populations  exist  [27,28,60–63].  The  fact  that  we  found
significant genetic heterogeneity for three SLC2A1 SNPs in
highly comparable (Caucasian) populations strongly suggests
that the genetic contribution to the heterogeneity of effect
observed in our study is substantial.
In  summary,  in  this  study  we  found  no  consistent
significant  association  between  three  SLC2A1  SNPs
(rs3754219,  rs4660687,  rs841853)  and  AMD.  The
heterogeneous findings on these three SLC2A1 SNPs provide
further  evidence  for  population-dependent  genetic  risk
heterogeneity in AMD [47,51–53]. Further studies in other,
ethnically  similar  and  diverse  populations  are  needed  to
falsify, confirm, or substantiate the potential role of SLC2A1
in AMD.
ACKNOWLEDGMENTS
This study was in part financed by an unrestricted research
grant from Merck Sharpe and Dohme and by the Algemene
Nederlandse Vereniging ter Voorkoming van Blindheid, The
Netherlands Macula Fund and LSBS (all to A.A.B). GWAS
genotype data for the Rotterdam Study is supported by the
Netherlands  Organization  for  Scientific  Research  (NWO)
Investments (nr.175.010.2005.011, 911–03–012). This study
is funded by the Research Institute for Diseases in the Elderly
(014–93–015; RIDE2), the Netherlands Genomics Initiative
(NGI)/ NWO project nr. 050–060–810, the EMC and Erasmus
University,  Netherlands  Organization  for  Health  Research
and  Development  (ZonMw),  the  Ministries  of  Education,
Culture and Science, and Health, Welfare and Sports, the
European Commission, and the Municipality of Rotterdam.
The Franconian AMD study would like to thank Claudia N.
Keilhauer  (Department  of  Ophthalmology,  University  of
Würzburg, Germany) for recruiting individuals with AMD
and the control subjects. Kerstin Meier (Institute of Human
Genetics, University of Regensburg, Germany) for technical
assistance. AREDS was supported (in part) by the Intramural
Research Program of the National Cancer Institute, National
Institutes  of  Health.  The  Columbia  University  study  is
supported in part by the grants from the National Eye Institute
EY13435  and  EY017404;  the  Macula  Vision  Research
Foundation; Kaplen Foundation; Wigdeon Point Charitable
Foundations  and  an  unrestricted  grant  from  Research  to
Prevent  Blindness.  G.S.H  is  supported  by  an  unrestricted
NIHR24 grant to the Department of Ophthalmology & Visual
Sciences, University of Utah and a Senior Scientist Award
(GSH) from Research to Prevent Blindness, Inc. Baltimore,
MD, USA. The University of Iowa would like to thank Chris
Pappas for technical assistance.
REFERENCES
1. Congdon N, O'Colmain B, Klaver CC, Klein R, Munoz B,
Friedman DS, Kempen J, Taylor HR, Mitchell P. Causes and
prevalence of visual impairment among adults in the United
States.  Arch  Ophthalmol  2004;  122:477-85.  [PMID:
15078664]
2. Friedman DS, O'Colmain BJ, Munoz B, Tomany SC, McCarty
C,  de  Jong  PT,  Nemesure  B,  Mitchell  P,  Kempen  J.
Prevalence of age-related macular degeneration in the United
States.  Arch  Ophthalmol  2004;  122:564-72.  [PMID:
15078675]
3. Vingerling  JR,  Dielemans  I,  Hofman  A,  Grobbee  DE,
Hijmering M, Kramer CF, de Jong PT. The prevalence of age-
related maculopathy in the Rotterdam Study. Ophthalmology
1995; 102:205-10. [PMID: 7862408]
4. Booij JC, Baas DC, Beisekeeva J, Gorgels TG, Bergen AA. The
dynamic nature of Bruch's membrane. Prog Retin Eye Res
2010; 29:1-18. [PMID: 19747980]
5. Booij JC, Kaing S, Ten Brink JB, Gorgels TG, van der Spek PJ,
Lengyel I, Bergen AA. On the origin of proteins in Bruch's
membrane  and  drusen.  BMC  Genomics.    [PMID:
19379482]Submitted
6. Seddon JM, Cote J, Page WF, Aggen SH, Neale MC. The US
twin study of age-related macular degeneration: relative roles
of genetic and environmental influences. Arch Ophthalmol
2005; 123:321-7. [PMID: 15767473]
7. Coleman HR, Chan CC, Ferris FL III, Chew EY. Age-related
macular degeneration. Lancet 2008; 372:1835-45. [PMID:
19027484]
8. Edwards AO, Ritter R III, Abel KJ, Manning A, Panhuysen C,
Farrer LA. Complement factor H polymorphism and age-
related  macular  degeneration.  Science  2005;  308:421-4.
[PMID: 15761121]
9. Fagerness JA, Maller JB, Neale BM, Reynolds RC, Daly MJ,
Seddon JM. Variation near complement factor I is associated
with  risk  of  advanced  AMD.  Eur  J  Hum  Genet  2009;
17:100-4. [PMID: 18685559]
10. Gold B, Merriam JE, Zernant J, Hancox LS, Taiber AJ, Gehrs
K, Cramer K, Neel J, Bergeron J, Barile GR, Smith RT,
Hageman GS, Dean M, Allikmets R. Variation in factor B
(BF) and complement component 2 (C2) genes is associated
with  age-related  macular  degeneration.  Nat  Genet  2006;
38:458-62. [PMID: 16518403]
Molecular Vision 2012; 18:657-674 <http://www.molvis.org/molvis/v18/a72> © 2012 Molecular Vision
66911. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C,
Henning  AK,  SanGiovanni  JP,  Mane  SM,  Mayne  ST,
Bracken  MB,  Ferris  FL,  Ott  J,  Barnstable  C,  Hoh  J.
Complement factor H polymorphism in age-related macular
degeneration. Science 2005; 308:385-9. [PMID: 15761122]
12. Kortvely E, Hauck SM, Duetsch G, Gloeckner CJ, Kremmer E,
Alge-Priglinger  CS,  Deeg  CA,  Ueffing  M.  ARMS2  is  a
constituent  of  the  extracellular  matrix  providing  a  link
between  familial  and  sporadic  age-related  macular
degenerations. Invest Ophthalmol Vis Sci 2010; 51:79-88.
[PMID: 19696174]
13. Yang Z, Camp NJ, Sun H, Tong Z, Gibbs D, Cameron DJ, Chen
H, Zhao Y, Pearson E, Li X, Chien J, Dewan A, Harmon J,
Bernstein PS, Shridhar V, Zabriskie NA, Hoh J, Howes K,
Zhang  K.  A  variant  of  the  HTRA1  gene  increases
susceptibility to age-related macular degeneration. Science
2006; 314:992-3. [PMID: 17053109]
14. Yates JR, Sepp T, Matharu BK, Khan JC, Thurlby DA, Shahid
H,  Clayton  DG,  Hayward  C,  Morgan  J,  Wright  AF,
Armbrecht AM, Dhillon B, Deary IJ, Redmond E, Bird AC,
Moore AT. Complement C3 variant and the risk of age-related
macular  degeneration.  N  Engl  J  Med  2007;  357:553-61.
[PMID: 17634448]
15. Strauss O. The retinal pigment epithelium in visual function.
Physiol Rev 2005; 85:845-81. [PMID: 15987797]
16. Miceli  MV,  Newsome  DA,  Schriver  GW.  Glucose  uptake,
hexose  monophosphate  shunt  activity,  and  oxygen
consumption in cultured human retinal pigment epithelial
cells. Invest Ophthalmol Vis Sci 1990; 31:277-83. [PMID:
2303329]
17. Diehn JJ, Diehn M, Marmor MF, Brown PO. Differential gene
expression in anatomical compartments of the human eye.
Genome Biol 2005; 6:R74. [PMID: 16168081]
18. Kumagai AK, Glasgow BJ, Pardridge WM. GLUT1 glucose
transporter expression in the diabetic and nondiabetic human
eye. Invest Ophthalmol Vis Sci 1994; 35:2887-94. [PMID:
8188484]
19. Mantych GJ, Hageman GS, Devaskar SU. Characterization of
glucose  transporter  isoforms  in  the  adult  and  developing
human  eye.  Endocrinology  1993;  133:600-7.  [PMID:
8344201]
20. Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of
oxidative stress in the pathogenesis of age-related macular
degeneration.  Surv  Ophthalmol  2000;  45:115-34.  [PMID:
11033038]
21. Fernandes R, Hosoya K, Pereira P. Reactive oxygen species
downregulate glucose transport system in retinal endothelial
cells. Am J Physiol Cell Physiol 2011; 300:C927-36. [PMID:
21228321]
22. Takagi H, King GL, Aiello LP. Hypoxia upregulates glucose
transport activity through an adenosine-mediated increase of
GLUT1  expression  in  retinal  capillary  endothelial  cells.
Diabetes 1998; 47:1480-8. [PMID: 9726238]
23. Obrosova  IG,  Drel  VR,  Kumagai  AK,  Szabo  C,  Pacher  P,
Stevens MJ. Early diabetes-induced biochemical changes in
the retina: comparison of rat and mouse models. Diabetologia
2006; 49:2525-33. [PMID: 16896942]
24. Obrosova  IG,  Minchenko  AG,  Marinescu  V,  Fathallah  L,
Kennedy  A,  Stockert  CM,  Frank  RN,  Stevens  MJ.
Antioxidants attenuate early upregulation of retinal vascular
endothelial  growth  factor  in  streptozotocin-diabetic  rats.
Diabetologia 2001; 44:1102-10. [PMID: 11596663]
25. Roy  MS,  Hallman  DM,  Fu  YP,  Machado  M,  Hanis  CL.
Assessment of 193 candidate genes for retinopathy in African
Americans  with  type  1  diabetes.  Arch  Ophthalmol  2009;
127:605-12. [PMID: 19433708]
26. Pontiroli AE, Capra F, Veglia F, Ferrari M, Xiang KS, Bell GI,
Baroni MG, Galton DJ, Weaver JU, Hitman GA, Kopelman
PG,  Mohan  V,  Viswanathan  M.  Genetic  contribution  of
polymorphism  of  the  GLUT1  and  GLUT4  genes  to  the
susceptibility  to  type  2  (non-insulin-dependent)  diabetes
mellitus  in  different  populations.  Acta  Diabetol  1996;
33:193-7. [PMID: 8904924]
27. Grzeszczak  W,  Moczulski  DK,  Zychma  M,  Zukowska-
Szczechowska E, Trautsolt W, Szydlowska I. Role of GLUT1
gene  in  susceptibility  to  diabetic  nephropathy  in  type  2
diabetes. Kidney Int 2001; 59:631-6. [PMID: 11168944]
28. Hodgkinson AD, Millward BA, Demaine AG. Polymorphisms
of the glucose transporter (GLUT1) gene are associated with
diabetic nephropathy. Kidney Int 2001; 59:985-9. [PMID:
11231353]
29. Page  T,  Hodgkinson  AD,  Ollerenshaw  M,  Hammonds  JC,
Demaine  AG.  Glucose  transporter  polymorphisms  are
associated  with  clear-cell  renal  carcinoma.  Cancer  Genet
Cytogenet 2005; 163:151-5. [PMID: 16337858]
30. Nicchia GP, Frigeri A, Liuzzi GM, Svelto M. Inhibition of
aquaporin-4 expression in astrocytes by RNAi determines
alteration in cell morphology, growth, and water transport and
induces changes in ischemia-related genes. FASEB J 2003;
17:1508-10. [PMID: 12824287]
31. Kalaria RN, Harik SI. Reduced glucose transporter at the blood-
brain barrier and in cerebral cortex in Alzheimer disease. J
Neurochem 1989; 53:1083-8. [PMID: 2769254]
32. Janigro D. Blood-brain barrier, ion homeostatis and epilepsy:
possible implications towards the understanding of ketogenic
diet  mechanisms.  Epilepsy  Res  1999;  37:223-32.  [PMID:
10584972]
33. Khandhadia S, Lotery A. Oxidation and age-related macular
degeneration: insights from molecular biology. Expert Rev
Mol Med 2010; 12:e34. [PMID: 20959033]
34. van Leeuwen R, Boekhoorn S, Vingerling JR, Witteman JC,
Klaver  CC,  Hofman  A,  de  Jong  PT.  Dietary  intake  of
antioxidants and risk of age-related macular degeneration.
JAMA 2005; 294:3101-7. [PMID: 16380590]
35. Zarbin MA. Current concepts in the pathogenesis of age-related
macular  degeneration.  Arch  Ophthalmol  2004;
122:598-614. [PMID: 15078679]
36. Baas DC, Ho L, Ennis S, Merriam JE, Tanck MW, Uitterlinden
AG,  de  Jong  PT,  Cree  AJ,  Griffiths  HL,  Rivadeneira  F,
Hofman A, van Duijn C, Smith RT, Barile GR, Gorgels TG,
Vingerling JR, Klaver CC, Lotery AJ, Allikmets R, Bergen
AA.  The  complement  component  5  gene  and  age-related
macular  degeneration.  Ophthalmology  2010;  117:500-11.
[PMID: 20022638]
37. Hofman A, van Duijn CM, Franco OH, Ikram MA, Janssen HL,
Klaver CC, Kuipers EJ, Nijsten TE, Stricker BH, Tiemeier H,
Uitterlinden  AG,  Vernooij  MW,  Witteman  JC.  The
Rotterdam Study: 2012 objectives and design update. Eur J
Epidemiol 2011; 26:657-86. [PMID: 21877163]
Molecular Vision 2012; 18:657-674 <http://www.molvis.org/molvis/v18/a72> © 2012 Molecular Vision
67038. Rivera A, Fisher SA, Fritsche LG, Keilhauer CN, Lichtner P,
Meitinger  T,  Weber  BH.  Hypothetical  LOC387715  is  a
second  major  susceptibility  gene  for  age-related  macular
degeneration,  contributing  independently  of  complement
factor H to disease risk. Hum Mol Genet 2005; 14:3227-36.
[PMID: 16174643]
39. Age-Related  Eye  Disease  Research  Group.  A  randomized,
placebo-controlled,  clinical  trial  of  high-dose
supplementation with vitamins C and E and beta carotene for
age-related cataract and vision loss: AREDS report no. 8.
Arch Ophthalmol 2001; 119:1417-36. [PMID: 11594942]
40. Bergeron-Sawitzke J, Gold B, Olsh A, Schlotterbeck S, Lemon
K, Visvanathan K, Allikmets R, Dean M. Multilocus analysis
of age-related macular degeneration. Eur J Hum Genet 2009;
17:1190-9. [PMID: 19259132]
41. Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber
AJ, Hardisty LI, Hageman JL, Stockman HA, Borchardt JD,
Gehrs KM, Smith RJ, Silvestri G, Russell SR, Klaver CC,
Barbazetto I, Chang S, Yannuzzi LA, Barile GR, Merriam JC,
Smith RT, Olsh AK, Bergeron J, Zernant J, Merriam JE, Gold
B,  Dean  M,  Allikmets  R.  A  common  haplotype  in  the
complement  regulatory  gene  factor  H  (HF1/CFH)
predisposes individuals to age-related macular degeneration.
Proc  Natl  Acad  Sci  USA  2005;  102:7227-32.  [PMID:
15870199]
42. Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G,
Davis MD, de Jong PT, Klaver CC, Klein BE, Klein R. An
international classification and grading system for age-related
maculopathy  and  age-related  macular  degeneration.  The
International  ARM  Epidemiological  Study  Group.  Surv
Ophthalmol 1995; 39:367-74. [PMID: 7604360]
43. The Age-Related Eye Disease Study Group. The Age-Related
Eye Disease Study system for classifying age-related macular
degeneration from stereoscopic color fundus photographs: the
Age-Related Eye Disease Study Report Number 6. Am J
Ophthalmol 2001; 132:668-81. [PMID: 11704028]
44. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and
visualization  of  LD  and  haplotype  maps.  Bioinformatics
2005; 21:263-5. [PMID: 15297300]
45. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA,
Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham
PC. PLINK: a tool set for whole-genome association and
population-based linkage analyses. Am J Hum Genet 2007;
81:559-75. [PMID: 17701901]
46. Ioannidis JP, Patsopoulos NA, Evangelou E. Heterogeneity in
meta-analyses  of  genome-wide  association  investigations.
PLoS ONE 2007; 2:e841. [PMID: 17786212]
47. Allikmets R, Dean M, Hageman GS, Baird PN, Klaver CC,
Bergen AA, Weber BH. The SERPING1 gene and age-related
macular  degeneration.  Lancet  2009;  374:875-6.  [PMID:
19748388]
48. Ioannidis JP. Why most published research findings are false.
PLoS Med 2005; 2:e124. [PMID: 16060722]
49. Hirschhorn  JN,  Lohmueller  K,  Byrne  E,  Hirschhorn  K.  A
comprehensive review of genetic association studies. Genet
Med 2002; 4:45-61. [PMID: 11882781]
50. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN.
Meta-analysis  of  genetic  association  studies  supports  a
contribution of common variants to susceptibility to common
disease. Nat Genet 2003; 33:177-82. [PMID: 12524541]
51. Yang Z, Stratton C, Francis PJ, Kleinman ME, Tan PL, Gibbs
D, Tong Z, Chen H, Constantine R, Yang X, Chen Y, Zeng J,
Davey L, Ma X, Hau VS, Wang C, Harmon J, Buehler J,
Pearson E, Patel S, Kaminoh Y, Watkins S, Luo L, Zabriskie
NA, Bernstein PS, Cho W, Schwager A, Hinton DR, Klein
ML, Hamon SC, Simmons E, Yu B, Campochiaro B, Sunness
JS, Campochiaro P, Jorde L, Parmigiani G, Zack DJ, Katsanis
N, Ambati J, Zhang K. Toll-like receptor 3 and geographic
atrophy in age-related macular degeneration. N Engl J Med
2008; 359:1456-63. [PMID: 18753640]
52. Ennis S, Jomary C, Mullins R, Cree A, Chen X, Macleod A,
Jones S, Collins A, Stone E, Lotery A. Association between
the SERPING1 gene and age-related macular degeneration: a
two-stage  case-control  study.  Lancet  2008;  372:1828-34.
[PMID: 18842294]
53. Cho Y, Wang JJ, Chew EY, Ferris FL III, Mitchell P, Chan CC,
Tuo  J.  Toll-like  receptor  polymorphisms  and  age-related
macular  degeneration:  replication  in  three  case-control
samples. Invest Ophthalmol Vis Sci 2009; 50:5614-8. [PMID:
19628747]
54. Zintzaras E, Stefanidis I. Association between the GLUT1 gene
polymorphism and the risk of diabetic nephropathy: a meta-
analysis. J Hum Genet 2005; 50:84-91. [PMID: 15682272]
55. Tao T, Tanizawa Y, Matsutani A, Matsubara A, Kaneko T,
Kaku K. HepG2/erythrocyte glucose transporter (GLUT1)
gene  in  NIDDM:  a  population  association  study  and
molecular scanning in Japanese subjects. Diabetologia 1995;
38:942-7. [PMID: 7589880]
56. Ng DPK, Canani L, Araki S, Smiles A, Moczulski D, Warram
JH, Krolewski AS. Minor effect of GLUT1 polymorphism on
susceptibility  to  diabetic  nephropathy  in  type  1  diabetes.
Diabetes 2002; 51:2264-9. [PMID: 12086959]
57. Attia J, Ioannidis JP, Thakkinstian A, McEvoy M, Scott RJ,
Minelli C, Thompson J, Infante-Rivard C, Guyatt G. How to
use an article about genetic association: B: Are the results of
the study valid? JAMA 2009; 301:191-7. [PMID: 19141767]
58. Miller MB, Schwander K, Rao DC. Genotyping errors and their
impact  on  genetic  analysis.  Adv  Genet  2008;  60:141-52.
[PMID: 18358319]
59. Lin PI, Vance JM, Pericak-Vance MA, Martin ER. No gene is
an island: the flip-flop phenomenon. Am J Hum Genet 2007;
80:531-8. [PMID: 17273975]
60. Gutierrez C, Vendrell J, Pastor R, Broch M, Aguilar C, Llor C,
Simon  I,  Richart  C.  GLUT1  gene  polymorphism  in  non-
insulin-dependent  diabetes  mellitus:  genetic  susceptibility
relationship  with  cardiovascular  risk  factors  and
microangiopathic  complications  in  a  Mediterranean
population. Diabetes Res Clin Pract 1998; 41:113-20. [PMID:
9789717]
61. Hodgkinson AD, Page T, Millward BA, Demaine AG. A novel
polymorphism  in  the  5′  flanking  region  of  the  glucose
transporter (GLUT1) gene is strongly associated with diabetic
nephropathy  in  patients  with  Type  1  diabetes  mellitus.  J
Diabetes Complications 2005; 19:65-9. [PMID: 15745834]
62. Liu  ZH,  Guan  TJ,  Chen  ZH,  Li  LS.  Glucose  transporter
(GLUT1) allele (XbaI-) associated with nephropathy in non-
insulin-dependent  diabetes  mellitus.  Kidney  Int  1999;
55:1843-8. [PMID: 10231446]
63. Makni K, Jarraya F, Rebai M, Mnif F, Boudawara M, Hamza
N, Rekik N, Abid M, Hachicha J, Granier C, Rebai A, Ayadi
Molecular Vision 2012; 18:657-674 <http://www.molvis.org/molvis/v18/a72> © 2012 Molecular Vision
671H. Risk genotypes and haplotypes of the GLUT1 gene for type
2 diabetic nephropathy in the Tunisian population. Ann Hum
Biol 2008; 35:490-8. [PMID: 18821326]
Molecular Vision 2012; 18:657-674 <http://www.molvis.org/molvis/v18/a72> © 2012 Molecular Vision
672Appendix  1.  Age-related  macular  degeneration  classification  per  study
sample.
AMD=age-related  macular  degeneration;
GA=geographic  athrophy;  CNV=choroidal
neovascularization;  Mixed  AMD=combination  of  GA  +
CNV. To access the data, click or select the words “Appendix
1.” This will initiate the download of a compressed (pdf)
archive that contains the file.
Appendix 2. Risk of AMD for SLC2A1 SNPs rs3754219, rs4660687 and
rs841853 in five replication populations.
AMD=age-related macular degeneration; CI=confidence
interval;  OR=odds  ratio;  SNP=single  nucleotide
polymorphism; m.a.f=minor allele frequency. “A” indicates
common allele, “a” minor allele. Percentages not always add
up to 100% because of conversion to whole numbers. ORs
were estimated by logistic regression. Adjustment for age and
gender only in the Rotterdam Study. To access the data, click
or  select  the  words  “Appendix  2.”  This  will  initiate  the
download of a compressed (pdf) archive that contains the file.
Appendix 3. Risk of AMD (subgroup) cases for SLC2A1 SNP rs3754219 in
five replication populations.
AMD=age-related macular degeneration; CI=confidence
interval;  OR=odds  ratio;  SNP=single  nucleotide
polymorphism;  m.a.f=minor  allele  frequency;
GA=geographic  athrophy;  CNV=choroidal
neovascularization;  Mixed  AMD=combination  of  GA  +
CNV; N.p=not performed. “A” indicates common allele, “a”
minor  allele.  Percentages  not  always  100%  because  of
conversion to whole numbers. ORs are estimated with logistic
regression analysis. Adjustment for age and gender only in the
Rotterdam study. To access the data, click or select the words
“Appendix 3.” This will initiate the download of a compressed
(pdf) archive that contains the file.
Appendix 4. Risk of AMD (subgroup) cases for SLC2A1 SNP rs4660687 in
five replication populations.
AMD=age-related macular degeneration; CI=confidence
interval;  OR=odds  ratio;  SNP=single  nucleotide
polymorphism;  m.a.f=minor  allele  frequency;
GA=geographic  athrophy;  CNV=choroidal
neovascularization;  Mixed  AMD=combination  of  GA  +
CNV; N.p=not performed. “A” indicates common allele, “a”
minor  allele.  Percentages  not  always  100%  because  of
conversion to whole numbers. ORs are estimated with logistic
regression analysis. Adjustment for age and gender only in the
Rotterdam study. To access the data, click or select the words
“Appendix 4.” This will initiate the download of a compressed
(pdf) archive that contains the file.
Appendix 5. Risk of AMD (subgroup) cases for SLC2A1 SNP rs841853 in
five replication populations.
AMD=age-related macular degeneration; CI=confidence
interval;  OR=odds  ratio;  SNP=single  nucleotide
polymorphism;  m.a.f=minor  allele  frequency;
GA=geographic  athrophy;  CNV=choroidal
neovascularization;  Mixed  AMD=combination  of  GA  +
CNV; N.p=not performed. “A” indicates common allele, “a”
minor  allele.  Percentages  not  always  100%  because  of
conversion to whole numbers. ORs are estimated with logistic
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673regression analysis. Adjustment for age and gender only in the
Rotterdam study. To access the data, click or select the words
“Appendix 5.” This will initiate the download of a compressed
(pdf) archive that contains the file.
Appendix 6. Comparison of genotype frequencies of the controls and AMD
(subgroup) cases between all study populations.
Genotype  frequencies  were  compared  by  using  the
Pearson  χ2 test. Abbreviations: AMD=age-related macular
degeneration;  GA=geographic  athrophy;  CNV=choroidal
neovascularization;  Mixed=combination  of  GA+CNV;
χ2=Chi square; df=degrees of freedom. To access the data,
click or select the words “Appendix 6.” This will initiate the
download of a compressed (pdf) archive that contains the file.
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